You are here

Article info

Article menu

This article has a correction. Please see:

Clinical/translational cancer immunotherapy
Original research
Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models

Authors

  • Vikash Kansal Department of Otolaryngology, Emory University School of Medicine, Atlanta, Georgia, USAWinship Cancer Institute, Emory University, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Andre J Burnham Department of Otolaryngology, Emory University School of Medicine, Atlanta, Georgia, USAWinship Cancer Institute, Emory University, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Brendan L C Kinney Department of Otolaryngology, Emory University School of Medicine, Atlanta, Georgia, USAWinship Cancer Institute, Emory University, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Nabil F Saba Winship Cancer Institute, Emory University, Atlanta, Georgia, USADepartment of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Chrystal Paulos Winship Cancer Institute, Emory University, Atlanta, Georgia, USADepartments of Surgery and Microbiology/Immunology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Gregory B Lesinski Winship Cancer Institute, Emory University, Atlanta, Georgia, USADepartment of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Zachary S Buchwald Winship Cancer Institute, Emory University, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Nicole C Schmitt Department of Otolaryngology, Emory University School of Medicine, Atlanta, Georgia, USAWinship Cancer Institute, Emory University, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles

Citation

Kansal V, Burnham AJ, Kinney BLC, et al
Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models
Journal for ImmunoTherapy of Cancer 2023;11:e005940. doi: 10.1136/jitc-2022-005940
Online issue publication 
December 07, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.